What is "tideglusib"

Tideglusib (NP-12, NP031112) is a potent, selective and irreversible small molecule non- ATP-competitive GSK3 inhibitor that has been investigated as a potential treatment for Alzheimer's disease and paralysis supranuclear palsy in Phase IIa and IIb clinical trials. The first clinical trial conducted with tideglusib to be published (in English, at least) was phase II and demonstrated that overall tideglusib was well tolerated, except for some moderate, asymptomatic, fully reversible increases in liver enzymes (≥2.5xULN; where ULN=Upper Limit of Normal).